Study provides genomic insights into treatment resistance in SMARCA4-mutant lung cancer
SMARCA4 – a gene that helps in chromatin remodeling – frequently is mutated in lung cancer, leading to immunotherapy resistance and a poor prognosis. To understand the underlying mechanisms, researchers led by Yonathan Lissanu, M.D., Ph.D., examined its role in lab models of SMARCA4-mutant lung cancer. SMARCA4 loss led to a decreased response to anti-PD1 immunotherapy and was associated with lower infiltration of CD4+ T cells and...
Phase II study identifies potential biomarkers in HPV-positive anal cancer
Cytotoxic chemotherapy is the standard of care for patients with unresectable and metastatic squamous cell carcinoma of the anal canal – a...
Bioinformatics chatbot can analyze large-scale cancer proteomics data
Comprehensive cancer omics initiatives like The Cancer Genome Atlas (TCGA) provide a wealth of DNA and RNA data, but little is known about...
Combination therapy yields strong long-term overall response rate in newly diagnosed acute myeloid leukemia patients
Intensive chemotherapy remains the standard treatment option for medically fit patients with newly diagnosed acute myeloid leukemia (AML). However, many patients face relapse. In a Phase II trial led by Courtney DiNardo, M.D., patients with newly diagnosed and relapsed/refractory AML were treated with a novel combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) combined with venetoclax...
Study offers insights into evolutionary process driving pancreatic cancer aggressiveness
Pancreatic cancer is hard to treat because of its heterogeneity, a characteristic frequently sustained by the ability of cells to change states...
Researchers identify epigenetic biomarker for breast cancer metastatic relapse
Cancer cells that initiate metastasis at secondary sites often enter a dormant state, allowing them to evade treatment and later reawaken...
Surgery enhances immunotherapy in advanced kidney cancer
Patients with advanced solid tumors are usually ineligible for surgery. However, surgically removing the primary tumor in preclinical models...